BusinessNeos Therapeutics to Host Fourth Quarter and Year-End 2016 Financial Results Conference Call on March 14, 2017By Nasdaq OMXMar 8, 2017, 12:30 PM UTC
BusinessNeos Therapeutics to Present at the Cowen and Company 37th Annual Health Care ConferenceBy Nasdaq OMXFeb 28, 2017, 12:30 PM UTC
BusinessNeos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare ConferenceBy Nasdaq OMXFeb 16, 2017, 12:30 PM UTC
BusinessCORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective StudyBy Nasdaq OMXJan 24, 2017, 6:04 PM UTC
BusinessImproved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective StudyBy Nasdaq OMXJan 10, 2017, 4:33 PM UTC
BusinessNeos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHDBy Nasdaq OMXDec 20, 2016, 12:30 PM UTC
BusinessNeos Therapeutics to Present at BMO Prescription for Success Healthcare ConferenceBy Nasdaq OMXDec 7, 2016, 1:00 PM UTC
BusinessNeos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHDBy Nasdaq OMXNov 17, 2016, 1:00 PM UTC
